Trials / Withdrawn
WithdrawnNCT04738175
Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19
A Randomized, Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of STI-2020 (COVI-AMG™) to Treat COVID-19
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sorrento Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push.
Detailed description
Subjects will receive a single injection of 40, 100, or 200 mg COVI-AMG or placebo via IV push. Subjects will be followed for 70 days after dosing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | COVI-AMG | COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb) |
| DRUG | Placebo | Diluent solution |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2021-11-01
- Completion
- 2021-11-01
- First posted
- 2021-02-04
- Last updated
- 2022-02-25
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04738175. Inclusion in this directory is not an endorsement.